Retrospective Description of the Safety and Efficacy of Filgrastim-sndz as a Front-line Mobilization Agent in Combination with Plerixafor followed by Post autologous stem cell infusion use for Autologous peripheral blood stem transplantation in Multiple Myeloma

Abstract

Purpose Mobilization of hematopoietic stem cells, which has largely replaced bone marrow harvesting as a source of hematopoietic stem cells, utilizing filgrastim and/or plerixafor for peripheral blood stem cell collection for autologous stem cell transplantation. Current data has shown equicoval efficacy with G-CSF based mobilization, however, there has been little data with the combination of a biosimilar and plerixafor in upfront stem cell mobilization. Here we evaluate our institutional outcomes in this setting. Methods This study was a descriptive retrospective chart review. This study included all patients treated with filgrastin-sndz and filgrastim from January 1st 2016 to December 31st 2017, diagnosed with multiple myeloma. There was a total of 48 patients included in the study that met all of the criteria. The CD34+ cells/kg count and adverse events were all analyzed Results A total of 46 patients participated in this study. The goal of it was to collect an average of CD34+ stem cells > 7 x 106/kg. The average collected CD34+ stem cells was 14.7 x 106/kg. The average number of apheresis sessions was 3.59 and none of the patients has an adverse effect from the infusion of filgrastim-sdnz. The average days to 500 ANC and was 13.54 and the average days to platelet count of 50,000 was 22.82. Conclusions Patients treated with filgrastin-sndz had the expected outcomes and had similar adverse reactions to that of filgrastim when compared to other studies.